GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (LTS:0SGC) » Definitions » Cyclically Adjusted FCF per Share

Arbutus Biopharma (LTS:0SGC) Cyclically Adjusted FCF per Share : $-1.05 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Arbutus Biopharma's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.055. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.05 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -12.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -9.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Arbutus Biopharma was 0.50% per year. The lowest was -14.80% per year. And the median was -8.75% per year.

As of today (2025-05-10), Arbutus Biopharma's current stock price is $3.3188. Arbutus Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-1.05. Arbutus Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Arbutus Biopharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted FCF per Share Chart

Arbutus Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.75 -1.18 -1.06 -1.05

Arbutus Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 -1.15 -1.10 -1.07 -1.05

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

Arbutus Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arbutus Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.055/133.1571*133.1571
=-0.055

Current CPI (Dec. 2024) = 133.1571.

Arbutus Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -0.595 99.621 -0.795
201506 -0.314 100.684 -0.415
201509 -0.061 100.392 -0.081
201512 -0.379 99.792 -0.506
201603 -0.230 100.470 -0.305
201606 -0.337 101.688 -0.441
201609 -0.277 101.861 -0.362
201612 -0.319 101.863 -0.417
201703 -0.386 102.862 -0.500
201706 -0.150 103.349 -0.193
201709 -0.296 104.136 -0.378
201712 -0.191 104.011 -0.245
201803 -0.367 105.290 -0.464
201806 -0.319 106.317 -0.400
201809 -0.243 106.507 -0.304
201812 -0.312 105.998 -0.392
201903 -0.298 107.251 -0.370
201906 -0.314 108.070 -0.387
201909 -0.417 108.329 -0.513
201912 -0.227 108.420 -0.279
202003 -0.228 108.902 -0.279
202006 -0.126 108.767 -0.154
202009 -0.153 109.815 -0.186
202012 -0.174 109.897 -0.211
202103 -0.192 111.754 -0.229
202106 -0.151 114.631 -0.175
202109 -0.159 115.734 -0.183
202112 -0.147 117.630 -0.166
202203 0.138 121.301 0.151
202206 -0.138 125.017 -0.147
202209 -0.124 125.227 -0.132
202212 -0.110 125.222 -0.117
202303 -0.170 127.348 -0.178
202306 -0.123 128.729 -0.127
202309 -0.130 129.860 -0.133
202312 -0.103 129.419 -0.106
202403 -0.110 131.776 -0.111
202406 -0.077 132.554 -0.077
202409 -0.110 133.029 -0.110
202412 -0.055 133.157 -0.055

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Arbutus Biopharma  (LTS:0SGC) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Arbutus Biopharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma Business Description

Industry
Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Headlines

No Headlines